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Introduction
The European Nutrigenomics Organisation (NuGO;
www.nugo.org) was established in 2004 and is funded
within the Sixth Framework Programme of the European
Commission as a network of excellence [4]. The core
partners forming NuGO are 23 research units based at
universities and research centers. The key objectives of
NuGO are: (a) the promotion of molecular nutrition
research in Europe; (b) the development and promotion of
mechanistic research in nutrition, food and health research
by application of omics technologies; and (c) to develop
joint research programs. The NuGO Proof of Principle
Study package (NuGO PPS) started in 2007 and is one of
the collaborative research initiatives within NuGO. The
main goals of the NuGO PPS are to: (a) assess the
advantages and the limitations of omics applications in
nutritional studies; (b) prove that systems biology
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disease status of an organism; (c) prove NuGO’s ability as
a network of excellence to analyze complex data sets
obtained from a federated series of studies, performed at
many partner sites, analyzed in different omics platforms in
combination with statistics and bioinformatics in an inte-
grative way; and ﬁnally (d) optimize the convergence in
data sharing by implementing a data integration platform.
The organizational structure of the NuGO PPS com-
prises a core team formed by six leading scientists (C.A.D.,
R.M.E., M.G., R.K., M.M., B.v.O.) who deﬁned the
general outlines of the NuGO PPS, a coordinator team
(H.D., I.R.-A.), three main centers where the experimental
studies were performed and 12 centers where samples are
analyzed in a close relationship between ‘‘wet lab’’ and
‘‘dry-lab’’ scientists (Fig. 1). Moreover, there is a study
that links NuGO to another Framework 6 Integrated
Project, LIPGENE (www.ucd.ie/lipgene), which is an
integrated project on the theme of the metabolic syndrome.
The experimental research platform is based on three
mouse feeding trials, PPS1, PPS2, PPS3, and a human
volunteer trial referred to as the human PPS (both animal
and human studies are approved by their respective local
ethics committees). All studies are based on an energy
challenge and the acute and chronic effects on substrate
oxidation and inﬂammation status in addition to the long
term alterations and stability of energy homeostasis. The
mouse studies address the effects of time (PPS1) or met-
abolic challenges (PPS2) or dietary fat content (PPS3) on
the development of insulin resistance and the metabolic
consequences which are assessed by comprehensive phe-
notyping. Analysis takes into account the type of diet, the
time-dependency of changes and organ-speciﬁcity of
effects well as the ability of an organism to cope with
metabolic dietary stress (bolus of glucose). The human
study is designed to assess the biological intra- and inter-
individual variation of a huge spectrum of molecular,
metabolic and clinical parameters employing the different
omics technologies and to assess the scale and patterns of
alterations elicited by a simple nutritional intervention—a
36 h fasting period.
PPS1: development of insulin resistance on a high fat
diet in ApoE*3Leiden mice
The ApoE*3Leiden transgenic mouse is highly susceptible
to diet-induced hyperlipoproteinemia and has been estab-
lished as a valid murine atherosclerosis models mimicking
many hallmarks of human metabolism related to diabetes
and atherosclerosis [8].In ApoE*3Leiden transgenic mice,
the lipid metabolism is humanized (i.e., a more human-like
lipoprotein proﬁle). These humanized mice also can serve
as a model of insulin resistance. The mouse study was
designed and executed by T.K. and R.K., at TNO-Leiden
(The Netherlands) including microarray analysis of organs
relevant for insulin resistance (liver, adipose tissue, mus-
cle). Parts of the study were donated to NuGO and
biosamples are being further analyzed within the NuGO
PPS1 research community. The prime goal of the study is
to monitor, with high time-resolution, the development of
diet-induced obesity (DIO) and insulin resistance. To do so,
genome-wide transcriptomic datasets for the course of the
development of insulin resistance in liver, white adipose
tissue and muscle were generated. Within PPS1, the
development of hepatic steatosis is analyzed which
includes the development of a (subacute) inﬂammatory
response. Insulin resistance was achieved in the
ApoE*3Leiden mice by feeding animals a diet based on
45% fat by energy (beef tallow) over 12 weeks. Insulin
resistance was established in the animals by performing a
glucose tolerance test 3 day prior to sacriﬁce (and parallel
hyperinsulinemic-euglycemic clamp analyses in separate
mice). Tissue samples were collected at 0, 1, 6, 9 and
12 weeks (sacriﬁce of n = 15 animals per time point) and
plasma samples were taken in each animal at regular
intervals to be able to analyze intra-individual changes over
time. Three different adipose tissue depots (mesenteric,
abdominal subcutaneous and epididymal) are being ana-
lyzed by transcriptomics, histology and immunochemistry
to assess the response of the different depots to insulin
resistance and to obtain potential new biomarkers of adi-
pose tissue insulin resistance. These analyses will be
performed taking into consideration that the mesenteric
adipose tissue can be markedly contaminated by pancreatic
tissue in the proximal part of the mesenteric adipose depot
[2]. Pancreatic contamination of the mesenteric adipose
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123tissue can be minimized by discarding the proximal part of
the mesenterium located close to the pancreas. The liver is
being analyzed by transcriptomics, targeted proteomics as
well as histology and immunochemistry. In addition,
inﬂammation markers (for review: [5, 6]) are monitored in
liver and plasma to follow the progression of insulin
resistance and hepatic steatosis. Moreover, collaborations
have been established with other groups within NuGO to
analyze the impact of this metabolic challenge on colonic
tissues (G. Elliott and L. Lund, Institute of Food Research,
Norwich, UK).
PPS2: evaluation of the acute whole-body response
to glucose stress in C57BL/6J mice
PPS2 was designed to compare the whole-body response to
a metabolic stressor (glucose bolus) between healthy and
insulin resistant mice. Mice with an isogenic background
(C57BL/6J mice) were fed diets for 12 weeks containing
either 10 or 45% fat by energy (mainly palm oil) after
2 weeks of adaptation to laboratory conditions with a
control diet. Plasma was collected throughout the 12 weeks
of feeding to monitor the development of insulin resistance
establishing that animals on the high fat diet had developed
insulin resistance after 3 months. Healthy and insulin
resistant animals were subjected to a glucose tolerance test
at the end of the feeding trial followed by comprehensive
phenotyping. The core of the study was performed at TNO
(coordinated by R.K. and T.K.). Serum, liver and selected
tissues like muscle and adipose tissue were removed 0 min,
40 min, 2, 18 and 48 h after the glucose challenge. Glucose
was injected via the i.p. route at 1 p.m. in all groups and
animals had free access to feed during the challenge (no
fasting). The liver will be analyzed by transcriptomics, and
by proteomic and metabolomic approaches. Metabolomic
analysis is also being performed in muscle, another tissue
affected by insulin resistance, whilst serum is being ana-
lyzed by both proteomics and metabolomics. Moreover, the
collaborations mentioned in PPS1 have been established
here also to analyze the impact of this metabolic challenge
on colonic tissues.
PPS3: dose-dependent effects of dietary fat
on the organ-speciﬁc response in C57BL/6J mice
Prime aim of this study is to generate robust omics data sets
for the effects of diets comprised of increasing fat contents
on the organism. The core study was performed at Wa-
geningen University (coordinated by M.M. and M.V.B.).
C57BL/6J animals were fed diets with 10, 20, 30 and 45%
energy from fat for 4 weeks (after 2 weeks adaptation to a
control diet). Transcriptome analysis is being performed in
liver, small intestine, adipose tissue and muscle on samples
obtained after 0, 1 and 4 weeks of feeding. Moreover,
proteomic analysis of liver and muscle tissue is being car-
ried out on the same samples to enable direct comparison
with the transcriptomic data. Pancreatic tissue is analyzed at
the proteomic level due to its importance in insulin secre-
tion. And in collaborations with other NuGO groups colonic
(D. Haller and T. Werner, TUM) and brown adipose tissue
(M. Klingenspor and T. Fromme, TUM) are also being
analyzed. Since not only glucose and lipid metabolism but
Fig. 1 Organizational structure
of the NuGO Proof of Principle
Study Package. *Study donated
by TNO-Quality of Life. TNO-
Quality of Life, The
Netherlands; Wageningen
University, The Netherlands;
University of Aberdeen, Rowett
Institute of Nutrition and Health
(UoA), UK; University of Oslo,
Norway; Ancona University,
Italy; Maastricht University,
The Netherlands; University
College Dublin (UCD), Ireland;
Institut National de la
Recherche Agronomique
(INRA), France; Institute of
Food Research (IFR), UK;
Technische Universita ¨t
Mu ¨nchen (TUM), Germany;
Firenze University, Italy
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123also amino acid metabolism (5) are insulin-dependent and
change during a decline of tissue insulin sensitivity, another
aim of PPS3 is to assess whether changes in plasma amino
acid levels or patterns can serve as biomarkers of insulin
resistance. LC-MS/MS will be applied to quantify 45 amino
acids and derivatives in plasma samples collected every
second week from animals fed the 10 or the 45% energy
from fat diets over the 12-week period. Another study arm
embedded into PPS3 is comprised of a leptin challenge
(coordinated by B.deR. and L.M.W.). In this study we
perform transcriptomic analysis of the hypothalamus, pro-
teomic analysis histochemical analysis of hepatic cells in
mice fed 10 or 45% energy from fat for 1 or 4 weeks, with
or without an acute leptin challenge. This will allow us to
assess, at the tissue level, changes in leptin sensitivity and
alterations that are central to satiety and metabolic control
[1, 5]. Such changes will be related to plasma leptin and
glucose levels.
Human PPS: an intervention study
The human PPS represents a continuation and extension of
an established collaborative effort within NuGO based on
the PlasmaPlus Study in which four centers validated and
optimized proteome analysis from blood samples for bio-
marker discovery [3]. Main aims of the human PPS is to (1)
assess the biological intra-and inter-individual variance of
a huge spectrum of molecular, metabolic and clinical
parameters employing the different omics technologies at
baseline and after a 36 h fasting period, (2) identify com-
mon and unique changes in these parameters in response to
fasting, and 3) determine the most comprehensive and
sensitive omics approaches to detect and quantify the
effects of a nutritional fasting challenge in humans. The
human PPS enrolled ten healthy volunteers that were asked
to come to the Human Nutrition Unit in Aberdeen on four
different days of the week during four weeks after an
overnight fast to provide a blood sample (for the isolation
of plasma, platelets and PBMC), and a saliva and a
morning urine sample to assess intra- and interindividual
variations in baseline levels. On the fourth sampling day,
volunteers were fasted for an additional 24 h (total of 36 h)
and again plasma, saliva and urine samples as well as
circulating blood cells were collected for transcriptome,
proteome and metabolome analysis. The core study was
performed at the University of Aberdeen (coordinated by
B.deR. and S.J.D.). All samples are being submitted to
comprehensive proﬁling employing all omics technologies.
Biological variability and fasting responses are being
monitored in plasma, platelets, peripheral blood mononu-
clear cell (PBMC), urine and saliva by proteomics based on
2D-gel based platforms coupled to mass spectrometry for
protein identiﬁcation. Alterations in the PBMC transcrip-
tome are being analyzed by employing the Affymetrix
microarrays speciﬁcally designed for NuGO, and plasma
and urine sample metabolite proﬁling is achieved based on
NMR, GC-MS, GC-MS/MS and LC-MS/MS platforms
comprising non-targeted and targeted approaches. More-
over, a panel of 89 hormones, cytokines and chemokines
and metabolic factors was analyzed on a commercial
targeted proﬁling platform (RulesBasedMedicine, www.
rulesbasedmedicine.com). In this unique combination of
nutrigenomics tools this study should provide the most
comprehensive metabolic phenotyping possible in human
volunteers with minimal invasive methods for obtaining
appropriate biosamples.
Bioinformatic studies
All data generated in the four experimental studies are
being collected and analyzed using a central data ware-
house represented by the NuGO ‘‘black box system’’ also
comprising a NuGO-wide intranet platform for data pro-
cessing and analysis. A group of bioinformatic experts
(coordinated by C.E) is responsible for the analysis of the
data by different bioinformatic and biostatistics approa-
ches. The studies are focused on the statistical modeling
of the time-courses and organ-speciﬁc responses to the
dietary challenges with a particular focus on the transcript
proﬁling data sets. A second series of analysis uses the
time course results and targets integration of transcrip-
tomic, metabolomic and proteomic data by multivariate
analyses and at the pathway level by using, for example,
PathVisio [7]. In this issue Coort S. L. et al. and Baccini
M. et al. describe some of the biostatistical and bioin-
formatic approaches applied to the different study sections
with the NuGO PPS.
Standardization and integration
The NuGO PPS package is the outcome of a long process
of discussions between the nutrigenomics experts in the
network. Apart from the scientiﬁc innovation and excel-
lence mentioned previously, a prime prerequisite was that
all partners submitting proposals to join the PPS trial could
collaborate within a virtual research infrastructure. All
participants had to agree on the highest level of standard-
ization of the methodologies used and on standardized data
storage and data sharing policies. In fact, this study was
intended also as a proof of principle for the established
NuGO research infrastructure. The experimental designs of
two of the three mouse studies were harmonized by
deﬁning animals, age, gender, diets, fasting periods and the
150 Genes Nutr (2008) 3:147–151
123workﬂow in obtaining and processing the biosamples.
Shared analytical platforms such as the NuGO Affymetrix
gene chip, a common hybridization service as well as the
stream-lined data analysis should ensure the highest degree
of harmonized data generation and standardization. Also,
the NuGO PPS proﬁts from the infrastructure already
created in the previous years within NuGO such as the
array pipeline and the NuGO Black Box Project which is
formed by a federated network of computer servers
installed at all partners, allowing standardized storage,
sharing and processing of all data generated within the PPS
(Evelo et al. in press).
Conclusion
Here we present the NuGO Proof of Principle Study
package to the science community. This effort represents
one of the very few coordinated interdisciplinary and
multicenter research initiatives in the nutrigenomics ﬁeld.
The aims of the studies are to (1) improve understand of the
time-lines for the development of insulin resistance in
different organs under feeding regimens based on high fat
diets, (2) take the omics technologies to proof and (3) take
NuGO to proof as a network that is generating an ‘‘added
value’’ by sharing technology, data, knowledge and
expertise. In this respect not only mice and human volun-
teers are challenged but also the entire science community
under the NuGO (p)roof.
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